TIDMMXCT
RNS Number : 3349Z
MaxCyte, Inc.
14 March 2017
MaxCyte, Inc.
("MaxCyte")
CRISPR THERAPEUTICS/CASEBIA OBTAIN MAXCYTE COMMERCIAL
LICENSE
CRISPR Therapeutics and Casebia obtain commercial rights to
MaxCyte's cell engineering platform to develop CRISPR/Cas9-based
therapies
BASEL, Switzerland, CAMBRIDGE, Mass., USA & GAITHERSBURG,
Maryland, USA. Mar. 14th, 2017 - CRISPR Therapeutics (NASDAQ:CRSP),
a biopharmaceutical company focused on creating transformative
gene-based medicines for serious diseases, and Casebia
Therapeutics, a joint-venture established by CRISPR Therapeutics
and Bayer AG for developing CRISPR-based therapeutics in select
disease areas, today announced they have signed a joint commercial
license agreement with MaxCyte, Inc., a US-based global company
dedicated to accelerating the discovery, development, manufacturing
and commercialization of next-generation, cell-based medicines.
The commercial license builds on an existing research and
clinical licensing agreement for select disease areas. Under the
terms of the license, CRISPR Therapeutics and Casebia will obtain
non-exclusive commercial-use rights to MaxCyte's cell engineering
platform to develop CRISPR/Cas9-based therapies for
hemoglobin-related diseases and severe combined immunodeficiency
(SCID). MaxCyte will supply its systems to CRISPR Therapeutics and
Casebia as part of the license agreement and will receive upfront,
milestone, and sales-based payments.
"As we advance CRISPR Therapeutics' lead programs in
hemoglobinopathies to the clinic, it is important we prepare for
the future by securing our access to the leading ex vivo delivery
solution for both clinical and commercial use," said Samarth
Kulkarni, Chief Business Officer of CRISPR Therapeutics.
MaxCyte's Flow Electroporation(TM) Technology enables the
transfection of a variety of cell types at very high efficiency
while maintaining very high viability. CRISPR Therapeutics and
Casebia's lead programs rely on ex vivo gene editing, where the
CRISPR components are delivered to hematopoietic stem cells using
the MaxCyte technology.
"With Casebia and CRISPR Therapeutics working closely together,
we hope to make bold investments and accelerate our efforts to
access and acquire all the leading platform technologies necessary
to develop and commercialize CRISPR-based therapeutics," said Jim
Burns, President and CEO of Casebia.
"The initiation of this commercial license agreement with CRISPR
Therapeutics and Casebia, both leaders in gene editing, marks a
very important milestone for MaxCyte in executing our business
strategy and demonstrates the value of our platform and our
intellectual property, as well as our ability to collaborate
effectively with companies commercializing cell therapies," said
Doug Doerfler, President & CEO of MaxCyte, Inc.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on
developing transformative gene-based medicines for serious diseases
using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR /
Cas9 is a revolutionary technology that allows for precise,
directed changes to genomic DNA. The company's multi-disciplinary
team of world-class researchers and drug developers is working to
translate this technology into breakthrough human therapeutics in a
number of serious diseases. Additionally, CRISPR Therapeutics has
established strategic collaborations with Bayer AG and Vertex
Pharmaceuticals to develop CRISPR-based therapeutics in diseases
with high unmet need. The foundational CRISPR/Cas9 patent estate
for human therapeutic use was licensed from the company's
scientific founder Emmanuelle Charpentier, Ph.D. CRISPR
Therapeutics is headquartered in Basel, Switzerland with its
R&D operations based in Cambridge, Massachusetts. For more
information, please visit www.crisprtx.com.
About Casebia Therapeutics
Casebia Therapeutics is a joint venture between CRISPR
Therapeutics and Bayer AG, focused on discovering, developing and
commercializing new CRISPR/Cas9-based breakthrough therapeutics to
treat blood disorders, blindness, and heart disease. Formed in the
first quarter of 2016, the company began operations in the U.S. in
August of 2016. Casebia has access to gene-editing technology from
CRISPR Therapeutics in specific disease areas, as well as access to
protein engineering expertise and relevant disease know-how through
Bayer. Casebia is a free-standing entity, equally owned by CRISPR
Therapeutics and Bayer, with its own scientific leadership and
management team. The company's Board of Directors has equal
composition from CRISPR Therapeutics and Bayer. Casebia is
headquartered in Cambridge, MA with research operations in
Cambridge, MA, and San Francisco, CA.
About MaxCyte
MaxCyte (LSE: MXCT), is a US-based global company dedicated to
accelerating the discovery, development, manufacturing and
commercialization of next-generation, cell-based medicines. The
Company provides its patented, high-performance cell engineering
platform to biopharmaceutical partners engaged in drug discovery
and development, biomanufacturing, and cell therapy, including gene
editing and immuno-oncology. With its robust delivery platform,
MaxCyte's team of scientific experts helps its partners to unlock
their product potential and solve development and commercialization
challenges.
MaxCyte is currently partnering with commercial and academic
cell therapy developers in more than 40 licensed programs covering
a diverse range of fields, including immuno-oncology, gene editing,
and regenerative medicine. MaxCyte's Flow Electroporation(TM)
Technology offers seamless scalability, and can be used from early
discovery in a lab to the clinical environment, through to
regulatory drug approval for commercial production.
MaxCyte is also developing CARMA, its proprietary, breakthrough
platform in immuno-oncology, to rapidly manufacture CAR therapies
for a broad range of cancer indications, including solid tumors
where existing CAR-T approaches face significant challenges.
For more information, visit http://www.maxcyte.com/
CRISPR Forward-Looking Statement
Certain statements set forth in this press release constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including,
but not limited to, statements concerning: the therapeutic value,
development, and commercial potential of CRISPR/Cas-9 gene editing
technologies and therapies and the intellectual property protection
of our technology and therapies. You are cautioned that
forward-looking statements are inherently uncertain. Although the
company believes that such statements are based on reasonable
assumptions within the bounds of its knowledge of its business and
operations, the forward-looking statements are neither promises nor
guarantees and they are necessarily subject to a high degree of
uncertainty and risk. Actual performance and results may differ
materially from those projected or suggested in the forward-looking
statements due to various risks and uncertainties. These risks and
uncertainties include, among others: uncertainties inherent in the
initiation and completion of preclinical and clinical studies for
the Company's product candidates; uncertainties regarding the
intellectual property protection for our technology and
intellectual property belonging to third parties; availability and
timing of results from preclinical and clinical studies; whether
results from a preclinical trial will be predictive of future
results of the future trials; expectations for regulatory approvals
to conduct trials or to market products; and those risks and
uncertainties described in Item 1A under the heading "Risk Factors"
in the company's most recent annual report on Form 10-K, and in any
other subsequent filings made by the company with the U.S.
Securities and Exchange Commission (SEC), which are available on
the SEC's website at www.sec.gov. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date they
are made.
CRISPR CONTACTS:
Media:
Jennifer Paganelli
WCG for CRISPR
347-658-8290
jpaganelli@wcgworld.com
Investors:
Chris Brinzey
Westwicke Partners for CRISPR
339-970-2843
chris.brinzey@westwicke.com
CASEBIA CONTACTS:
Ann Stanesa
Ten Bridge Communications
ann@tenbridgecommunications.com
617-230-0347
MAXCYTE CONTACTS:
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer
+1-301-944-1620
dougd@maxcyte.com
Nominated Adviser and Broker:
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Duncan Monteith
Tom Salvesen (Corporate Broking)
+44 (0) 20 7886 2500
Financial PR Adviser:
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
Lindsey Neville
+44 (0)203 709 5700
maxcyte@consilium-comms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAFDDFEFXEAF
(END) Dow Jones Newswires
March 14, 2017 03:01 ET (07:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Sep 2023 to Sep 2024